Literature DB >> 29023641

Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study.

G Girolomoni1, S R Feldman2, P Emery3, J Ghil4, J W Keum4, S Y Cheong4, E Hong4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29023641     DOI： 10.1111/bjd.16032

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  8 in total

1.  The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases.

Authors:  Cosimo Bruni; Stefano Gentileschi; Giovanni Pacini; Caterina Baldi; Marco Capassoni; Lorenzo Tofani; Marco Bardelli; Laura Cometi; Luca Cantarini; Francesca Nacci; Michele Vietri; Francesca Bartoli; Ginevra Fiori; Bruno Frediani; Marco Matucci-Cerinic
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-10-13       Impact factor: 5.346

Review 2.  Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.

Authors:  Laura Chadwick; Sizheng Zhao; Eduardo Mysler; Robert J Moots
Journal:  Curr Rheumatol Rep       Date:  2018-11-09       Impact factor: 4.592

Review 3.  Era of biosimilars in rheumatology: reshaping the healthcare environment.

Authors:  Josef S Smolen; Joao Goncalves; Mark Quinn; Fabrizio Benedetti; Jake Yongkwon Lee
Journal:  RMD Open       Date:  2019-05-21

Review 4.  Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents.

Authors:  Vibeke Strand; Joao Gonçalves; Timothy P Hickling; Heather E Jones; Lisa Marshall; John D Isaacs
Journal:  BioDrugs       Date:  2020-02       Impact factor: 5.807

5.  Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars.

Authors:  Hans C Ebbers; Bjørn Fehrmann; Mette Ottosen; Niels Hvorslev; Pia Høier; Jae-Woong Hwang; Jinhan Chung; Hyoung Taek Lim; Shinjung Lee; Juyoung Hong; Mourad Farouk Rezk
Journal:  BioDrugs       Date:  2020-04       Impact factor: 5.807

6.  Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study.

Authors:  Simone Parisi; Andrea Becciolini; Maria Chiara Ditto; Davide Rozza; Anna Zanetti; Angela Laganà; Clara Lisa Peroni; Chiara Centanaro Di Vittorio; Rosanna Degiovanni; Cristina Realmuto; Carlo Alberto Scirè; Marta Priora; Eleonora Di Donato; Daniele Santilli; Flavio Mozzani; Gianluca Lucchini; Alarico Ariani; Lucia Gardelli; Francesco Girelli; Eugenio Arrigoni; Ilaria Platè; Elena Bravi; Marino Paroli; Rosalba Caccavale; Carlo Salvarani; Gilda Sandri; Federica Lumetti; Alessandro Volpe; Antonio Marchetta; Enrico Fusaro
Journal:  J Clin Med       Date:  2022-01-26       Impact factor: 4.241

7.  An etanercept O-glycovariant with enhanced potency.

Authors:  Thomas G Biel; Talia Faison; Alicia M Matthews; Guozhang Zou; Uriel Ortega-Rodriguez; Melissa A Pegues; Nicole Azer; Fabiola Gomez; Sarah Johnson; Sarah Rogstad; Kang Chen; Hang Xie; Cyrus Agarabi; V Ashutosh Rao; Tongzhong Ju
Journal:  Mol Ther Methods Clin Dev       Date:  2022-03-03       Impact factor: 6.698

Review 8.  Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review.

Authors:  Anja St Clair-Jones; Francesca Prignano; Joao Goncalves; Muriel Paul; Philipp Sewerin
Journal:  Rheumatol Ther       Date:  2020-11-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.